🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
14/01/2019 1,0700 USD
12/10/2018 0,9600 USD
12/07/2018 0,9600 USD
12/04/2018 0,9600 USD
11/01/2018 0,7100 USD
12/10/2017 0,6400 USD
12/07/2017 0,6400 USD
11/04/2017 0,6400 USD
11/01/2017 0,6400 USD
12/10/2016 0,5700 USD
13/07/2016 0,5700 USD
13/04/2016 0,5700 USD
13/01/2016 0,5700 USD
13/10/2015 0,5100 USD
13/07/2015 0,5100 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/02/2017 61,67 61,91 60,81 61,48 -0,28% 1,78% 5.662.000
15/02/2017 60,92 61,84 60,40 61,65 +1,36% 2,36% 8.927.600
14/02/2017 60,44 60,98 60,15 60,82 +0,51% 1,37% 13.562.200
13/02/2017 60,58 60,86 60,43 60,51 +0,15% 0,71% 6.396.000
10/02/2017 60,85 61,00 60,27 60,42 -0,69% 1,20% 5.749.200
09/02/2017 60,52 61,00 60,42 60,84 +0,53% 0,96% 4.324.600
08/02/2017 60,14 61,02 60,05 60,52 -0,07% 1,61% 5.357.800
07/02/2017 60,65 60,87 60,40 60,56 -0,15% 0,77% 4.210.300
06/02/2017 60,51 60,97 60,35 60,65 -0,03% 1,02% 5.358.100
03/02/2017 60,90 61,06 60,44 60,67 -0,36% 1,02% 6.470.300
02/02/2017 60,65 61,12 60,48 60,89 +0,00% 1,06% 5.365.300
01/02/2017 61,07 61,10 60,27 60,89 -0,36% 1,36% 5.888.700
31/01/2017 60,01 61,32 59,75 61,11 +1,13% 2,62% 8.149.800
30/01/2017 59,91 60,47 59,27 60,43 +0,72% 2,00% 7.792.700
27/01/2017 60,00 61,25 59,52 60,00 -2,07% 2,88% 14.151.200
26/01/2017 61,16 61,90 61,07 61,27 -0,18% 1,36% 7.765.300
25/01/2017 60,60 61,63 60,34 61,38 +1,32% 2,13% 8.052.800
24/01/2017 60,91 60,93 59,67 60,58 -0,62% 2,07% 6.642.000
23/01/2017 61,02 61,26 60,68 60,96 -0,31% 0,95% 5.244.700
20/01/2017 61,41 61,77 61,08 61,15 -0,37% 1,12% 6.730.000
19/01/2017 61,45 61,88 61,12 61,38 -0,45% 1,24% 5.384.200
18/01/2017 61,76 62,14 61,32 61,66 -0,32% 1,33% 5.519.400
17/01/2017 61,75 62,04 61,10 61,86 -0,21% 1,52% 8.446.700
13/01/2017 61,35 62,41 61,05 61,99 +1,16% 2,22% 7.295.100
12/01/2017 60,77 61,43 60,42 61,28 +0,23% 1,66% 8.194.400
11/01/2017 63,38 63,65 60,59 61,14 -4,57% 4,83% 13.565.200
10/01/2017 64,05 64,50 63,77 64,07 -0,22% 1,14% 6.523.500
09/01/2017 63,80 64,38 63,75 64,21 +0,66% 0,99% 8.794.500
06/01/2017 63,88 64,00 63,52 63,79 +0,03% 0,75% 4.722.300
05/01/2017 63,38 63,95 63,03 63,77 +0,76% 1,45% 5.359.400